Latest News

Princess Margaret Cancer Centre Innovation Acceleration Fund Announces New Recipients of Funding in Support of Early Stage Technology Development

June 20, 2019 /in Latest News

The Princess Margaret Cancer Foundation’s Innovation Accelerator Fund (IAF) Leadership Board has announced the first three funded projects of 2019.  The IAF was established by The Princess Margaret Cancer Foundation in collaboration with University Health Network’s Technology Development and Commercialization Office in January 2016 to help investigators at the Princess Margaret Cancer Centre accelerate their early-stage research discoveries towards commercialization.  The fund provides a maximum of $250,000 per proposal, helping to take novel technologies from bench-to-bedside. The three selected projects of this round include:

 

Preclinical Testing of Novel TCR-based Treatment for Cancer

Dr. Naoto Hirano, a Senior Scientist at the Princess Margaret Cancer Centre, was selected for an additional round of IAF funding to support the...

Read More

Drs. Shaf Keshavjee and Marcelo Cypel named joint UHN Inventor of the Year

June 13, 2019 /in Latest News

Drs. Shaf Keshavjee (L) and Marcelo Cypel have taken their invention through pre-clinical and clinical trials and achieved government approval, making it a fully-approved and funded clinical therapy. (Photo: UHN StRIDe Team)

Drs. Shaf Keshavjee and Marcelo Cypel were recognized yesterday as the joint-winners of UHN's 2018 Inventor of the Year by the UHN Technology Development & Commercialization Office (TDC). 

Each year, UHN's TDC awards and celebrates a UHN inventor or inventors who illustrate noteworthy excellence through inventiveness in research, critical contributions and commercial successes impacting patients and their quality of life.

Drs....

Read More

UHN Helping Make Toronto a Leader in Healthcare Innovation

May 28, 2019 /in Latest News
 
Thanks to JLABS for highlighting some of UHN's star researchers and their role in making Toronto a biotech destination!

Magic mix: Three ingredients that make Toronto a leader in healthcare innovation

By Allan Miranda, Head, JLABS Canada  May 23, 2019

Toronto, Ontario, Canada is becoming the next big technology hub for large global tech companies. From Google to Facebook to Uber, this city has attracted the world’s biggest tech companies to set up shop. In turn, this has attracted many new startups, including those in health care who are starting to call Toronto their home.

Johnson & Johnson Innovation – JLABS (JLABS @ Toronto) is one of Canada’s premier healthcare incubators. We are home to 50+ resident companies that are aiming to make advancements and developing new technologies...

Read More

LAB150 Innovation Award awarded to UHN's Brian Wu at Krembil Research Day

May 28, 2019 /in Latest News

LAB150 is a drug development collaboration between MaRS Innovation and a German-based CRO, Evotec SE, developed to accelerate Toronto’s academic research into market-ready products. With a combined multi-million-dollar financial commitment by MaRS Innovation and Evotec SE, this recently formed partnership aims to accelerate the development and commercialization of therapeutically focused programs and technologies with award amounts up to 400k USD.

LAB150 likes to recognize the community’s outstanding researchers committed to translating their academic research into novel therapeutic approaches that will ultimately improve patient care. As such, LAB150 was pleased to sponsor the “LAB150 Innovation Award” for UHN's Krembil Research Day. This award was presented to Krembil's Brian Wu for his work on Ephrin B2 Signaling in the Development of Pulmonary Fibrosis, who was the top-...

Read More

Takara Bio Inc. Licences UHN's New Generation CAR Gene Therapy

May 07, 2019 /in Latest News

Takara Bio to Acquire an Exclusive License to Use Patent Technology Relating to New Generation CAR Gene Therapy

Kusatsu/Shiga, Japan — April 26, 2019 – Takara Bio Inc. (Takara Bio) announces that it has entered into a worldwide license agreement with University Health Network in Canada*1  as of April 23, 2019, under which Takara Bio exclusively uses the patent technology relating to a new generation of CAR (Chimeric antigen receptor)*2 gene therapy. Takara Bio will develop the novel CAR gene therapy by leveraging the licensed technology, in cooperation with a group led by the patent inventor, Dr. Naoto Hirano, Associate Director for Research, Tumor Immunotherapy Program, Senior Scientist, Princess Margaret Cancer Centre / Professor of Medicine, Department of Immunology, University of Toronto (Toronto, Ontario, Canada).

In CAR...

Read More

UHN welcomes KITE, a new venture dedicated to rehabilitation research, science and commercialization

January 31, 2019 /in Latest News

UHN execs at KITE launch

On hand at TRI Research Day to introduce the change to staff and guests were: (L to R): Dr. Mark Bayley, Physiatrist in Chief & Medical Program Director, Toronto Rehab, Dr. Milos Popovic, Research Director, Toronto Rehab, Gillian Howard, VP, Public Affairs and Communications, UHN, Dr. Kevin Smith, President & CEO, UHN, Dr. Brad Wouters, EVP, Science and Research, UHN, and Dr. Geoff Fernie, former TRI Research Director. (Photo: UHN)

UHN is unveiling a new research institute designed to take the science of rehabilitation to new heights.   

Based at Toronto Rehab, the new institute, which will be known as KITE...

Read More

McEwen Stem Cell Institute Launched

December 07, 2018 /in Latest News

Announced on Dec 7, 2018

New Institute will accelerate work in regenerative medicine to help create new therapies.

   

On December 6, 2018, University Health Network (UHN) announced the creation of the McEwen Stem Cell Institute. The sixth institute within its research community, the McEwen Institute is focused on stem cell research and the promise of regenerative medicine and cell therapies.

Formerly the McEwen Centre for Regenerative Medicine, the evolution to the McEwen Stem Cell Institute signals the progress of the research since it was first formed in 2007. In collaboration with research institutions, clinical programs at UHN, and supporters from around the globe, investigators within...

Read More

UHN Remains Canada's Top Research Hospital in 2018!

November 15, 2018 /in Latest News

UHN buildings

Research Infosource Inc. list of Canada’s Top 40 Research Hospitals for 2018 shows research spending at the country’s leading research hospitals, hospital networks and health authorities rose 4.1 per cent to $2.65 billion in fiscal 2017, with UHN atop the list with $350.1 million. (Graphic: UHN)

​​UHN is once again ranked first on Canada's Top 40 Research Hospitals list for 2018.  

The list of top research hospitals across the country is compiled annually by Research Infosource Inc. 

UHN has appeared in the top position of the list every year since the rankings began in 2011.  

UHN's research expenditures for the 2017 fiscal year were $350.1 million, representing 17.3 per...

Read More

UHN's Dr. Sivak Snares the MaRS Innovation-Lab150/Evotec Award For Treating Glaucoma.

October 10, 2018 /in Latest News

Dr. Jeremy Sivak, Senior Scientist at the University Health Network (UHN)'s Krembil Research Institute snares the MaRS Innovation-LAB150/Evotec partnership award - the 1st ever at UHN and the 2nd ever under the partnership.

Dr. Sivak's project aims to develop a novel therapeutic approach to treat glaucoma, which is an irreversible neurodegenerative condition of the optic nerve; left untreated it can lead to blindness.  Glaucoma affects 1.9% of the population over 40 years of age and it is the leading cause of permanent blindness with over 70 million people affect worldwide.  

Dr. Sivak's team and collaborating scientists from the University of California at Berkeley (UC Berkeley) discovered a lipoxin with neuroprotective properties that has illustrated efficacy in preclinical glaucoma models.  With the award, Dr. Sivak will now team up with Dr. Mark Reed, who is a...

Read More

AVROBIO - UHN's Gene Therapy Start-up Announces Positive Phase 1 and 2 Clinical Data

October 01, 2018 /in Latest News

AVROBIO Inc, a UHN gene therapy start-up company, that recently IPO'ed on the NASDAQ (ticker symbol: "AVRO"), announced today that the initial clinical data for AVR-RD-01 gene therapy for AGA enzyme replacement in Fabry Disease patients were positive in both the Phase 1 and Phase II studies.

Read the full press release here: http://investors.avrobio.com/news-releases/news-release-details/avrobio-announces-updated-clinical-data-avr-rd-01-gene-therapy

 

 

 

Acumyn - UHN Spin-off Acquired

September 25, 2018 /in Latest News

Radiation therapy management software company Acumyn Inc. has been purchased by Elekta.

Acumyn Inc. was originally created by UHN in 2014 to commercialize AQUA radiation therapy management software.

 

A University Health Network spin-off company known as Acumyn Inc. was recently acquired by global radiotherapy giant Elekta.

Acumyn was created by UHN’s Technology Development and Commercialization (TDC) office to commercialize AQUATM, a software platform developed at Princess Margaret by a team led by Dr. Daniel...

Read More

UHN's start-up MolecuLight® Inc receives FDA De Novo clearance - Readies to enter the US wound care market

August 14, 2018 /in Latest News

 

Toronto-based, University Health Network (UHN) start-up company, MolecuLight® Inc. announced today that it has achieved a key regulatory milestone by receiving FDA's De Novo clearance for a first-of-its-kind handheld fluorescence imaging device, the MolecuLight i:X.

The MolecuLight i:X device captures and documents digital fluorescence information from wounds and tissue surrounding the wound site with real time videos and still images.  This point-of-care device has been optimized to be portable, compact, and eliminates the use of contrast agents. 

MolecuLight® Inc., will now be able to provide the MolecuLight i:X as a prescription-use only point-of-care imaging device to clinicians in the USA.  In turn...

Read More

AVROBIO IPO'S on NASDAQ - Raises over US$100 Million

July 30, 2018 /in Latest News

The University of Health Network (UHN)'s spinout - AVROBIO Inc - a recently public gene therapy biotechnology company raised over US$100 Million in it's initial public offering (IPO) on the NASDAQ stock exchange.  Less than one month of going public, AVROBIO it trading with a market cap of greater than US$651 Million.  AVROBIO is trading on the NASDAQ under the ticker symbol "AVRO".

AVROBIO, founded on the research done by Dr. Christopher Paige (UHN Senior Scientist;...

Read More

Shaping the Future of Cancer Treatment Systems - UHN’S Princess Margaret Cancer Centre Partner’s with RaySearch

July 30, 2018 /in Latest News

 

University Health Network (UHN)’s Princess Margaret Cancer Centre (PMCC) is continuing to push the envelope on cancer treatment workflows.  By partnering with RaySearch Laboratories AB (Sweden), the PMCC is joining forces to further develop RayCare®, a groundbreaking oncology informatics platform designed specifically to address unmet clinical workflow needs of cancer treatment.

Mary Gospodarowicz, medical director at PMCC, underlines the importance of this strategic collaboration with RaySearch toward offering patients comprehensive cancer care – a key priority at the Princess Margaret Cancer Centre.  Through RayCare®, “an integrated cancer informatics platform … the collaboration will [help] shape...

Read More

UHN's Medical Devices Spinoff Thornhill Medical Raises Fully Subscribed Series A Financing

July 18, 2018 /in Latest News

FOR IMMEDIATE RELEASE

 

Thornhill Medical Completes ‘Series A’ Financing Round Led by Shanghai based Yonghua Investment Management Co., Ltd.

 

Toronto, Canada – July 18, 2018

 

Thornhill Medical (Thornhill), a Canadian based medical device developer announced that it has completed its ‘Series A’ offering being fully subscribed by Yonghua Investment Management Co., Ltd. (“Yonghua Capital”) of Shanghai, PRC. Thornhill Medical will use the funding to support working capital for its market released line of emergency mobile products, expand its global sales and marketing presence and continue clinical research in the fields of non-invasive cardiac and brain stress testing.

 

“The financial investment focus of the Yonghua Capital compliments Thornhill’s approach to clinical research, product development and...

Read More

UHN's Technology-based AVROBIO Turning Heads in Gene Therapy

July 18, 2018 /in Latest News

 

AVROBIO Inc., is a clinical stage gene therapy company that is on the path to develop potentially curative lentiviral-based gene therapies for rare genetic diseases known as lysosomal storage diseases.  AVROBIO's approach is to use hemapoietic stem cells extracted from patients, modify these stems cells with lentiviral vectors, and insert a functional copy of the defective gene of the respective rare target disease.  Today lysosomal storage diseases are managed by enzyme replacement therapies, also known as ERTs, and represent a substantial global market of approximately US$ 4 Billion in net sales (2017).  AVROBIO's initial pipeline consists of 4 lentiviral-based gene therapies for the treatment of Fabry Disease, Gaucher Disease, Pompe Disease and Cystinosis.

Read more here:...

Read More

Drs. Gordon Keller & Laflamme Named Joint UHN Inventor of the Year!

June 13, 2018 /in Latest News

 

Yesterday, Brad Wouters, Executive Vice President, Science & Research presented the prestigious 15th Annual UHN Inventor of the Year Award (2017) to the duo of Dr. Gordon Keller and Dr. Michael Laflamme for their pioneering research and study of stem cells and in the field of Regenerative Medicine.  Drs. Keller and Laflamme were selected as co-winners from an outstanding pool of nominees by UHN's Technology Development and Commercialization (TDC) office for their research inventiveness, instrumental contributions and commercial successes toward impacting patient lives and their quality of life.

Dr. Keller is director of the McEwen Centre for Regenerative Medicine, which was founded by the generous support of Rob and Cheryl McEwen, and a Senior Scientist at Princess Margaret Cancer Centre at UHN.  Dr. Laflamme is the...

Read More

ARTIFICIAL INTELLIGENCE-DRIVEN 'MACHINE CLASSIFIERS' FOR ACCURATE DIAGNOSIS

May 29, 2018 /in Latest News

As medical technologies advance, personalized medicine is increasingly driving the classification and diagnosis of not only commonly seen, but also never encountered types and subtypes of disease conditions.  For pathologists and diagnosticians, this trend has increased the differential diagnostic demands, sample or test processing workflows and subspecialty training requirements.

Dr. Phedias Diamandis, a neuropathologist at the University Health Network (UHN) and an affiliate scientist at the Princess Margaret Cancer Centre is addressing just that.

Leveraging the power of deep convolutional neural networks (CNNs), Dr. Diamandis and his research team are developing diagnostic ‘machine classifiers’ – Artificial Intelligence (AI)–driven tools to enhance the capability of pathologists to quickly and...

Read More

Princess Margaret Cancer Centre Innovation Acceleration Fund Announces 1st Round of 2018 Awards to Researchers to Develop Early Stage Technologies

March 19, 2018 /in Latest News

 

Generation of inhibitors targeting general control nonderepressible 2 (GCN2) as a novel targeted therapy for ovarian cancer

Drs. Tracy McGaha and Robert Rottapel, Senior Scientists at UHN’s Princess Margaret Cancer Centre, along with their teams were awarded funding to support the discovery and development of small molecule inhibitors of GCN2 as a novel therapeutic mechanism for targeted therapy of ovarian cancer.

Ovarian cancer is the leading cause of death from gynecologic cancer in Canada with a 5-year survival of only 44%, underscoring the need for novel treatment strategies beyond conventional chemotherapy alone.  GCN2 is a key factor that controls the cellular stress response in conditions of low amino acid availability; the McGaha/Rottapel team has identified GCN2 as a key contributor to suppression of inflammatory anti-tumor...

Read More

UHN Start-up Nanovista Inc. closes $2.3 million seed round to advance its multimodal visualization agent towards clinical trials

February 13, 2018 /in Latest News

 

Toronto, Canada – Nanovista Inc. (“Nanovista”) develops multimodal visualization agents designed to improve the performance of image-guided high-precision cancer therapy. The seed round financing was led by GreenSky Capital Inc. and its affiliated venture funds, the GreenSky Accelerator Funds I and GreenSky Accelerator Funds II, who made a $750,000 lead investment as part of a $2.3M seed round investment.

Nanovista was founded by a world-renowned team of scientists within the University Health Network and the University of Toronto and supported by top clinical oncologists. Nanovista’s first product, comprised of a stable lipid-based nanotechnology, provides long lasting illumination of tumors during the surgical planning stage and inside the operating room with the potential to significantly improve outcomes of cancer surgeries. Along with her co-...

Read More